Du är här

2016-03-14

Photocure ASA: Photocure ASA Hexvix® data presented during the European Association of Urology congress

Hexvix real world evidence show improved recurrence free survival and health
care savings

Oslo, Norway, 14 March 2016: Photocure ASA (OSE: PHO), a specialty
pharmaceutical company focused on photodynamic technologies in dermatology
and cancer, is pleased to announce presentations by urology researchers on
Hexvix during the European Association of Urology (EAU) annual meeting held
in Munich, Germany 11-15 March 2016. The EAU is one of the largest
International meetings in urology, showcasing the latest and most relevant
knowledge with more than 12,000 urologists and exhibitors from over 100
countries. Hexvix is a photosensitizing agent taken up selectively by the
tumor cells in the bladder that when exposed to blue light during a
cystoscopic procedure results in a bright pink fluorescence of the suspicious
tissue. Using Hexvix as an adjunct to standard white light cystoscopy
enables the urologist to better detect and remove lesions, leading to a
reduced risk of recurrence.

Dr. Kjetil Hestdal, President &CEO of Photocure ASA comments: "We are
delighted to see the expanding body of evidence supporting Hexvix and its
role in the detection and management of bladder cancer. Real world data now
demonstrates the clinical and health economic benefits of Hexvix in a
day-to-day clinic setting supporting its widespread use. As more urologists
are exposed to the continued flow of data with Hexvix, more patients will
have access to its substantive benefits."

The Hexvix evidence from theory with its unique mode of action, randomized
clinical trials, and real world evidence were presented by Professor Dr.
Maximillian Burger, Chair of Urology of the University of Regensburg during a
symposium "Moving Forward in Urological Cancers" sponsored by Ipsen
Uro-oncology, strategic commercialization partner for Hexvix in Europe,
excluding the Nordic region.

Burger highlighted that bladder cancer is often under recognized and
undertreated. Despite the large majority of the audience voting that they
follow the guidelines he stated that there is still room for improvement. He
concluded that "Hexvix has been proven to offer significant benefits in the
detection and reduction in recurrence rates and emerging real world evidence
now confirms these findings, and even indicates better patient outcomes-
especially in high risk non-muscle invasive bladder cancer (NMIBC) patients,
where it matters most. The strong real world data can give us even more
confidence managing patients in our daily clinical practice. It improves
recurrence free survival and there are significant savings to the health care
system as every third follow up TURB can be avoided."

Hexvix is recommended for use in the diagnosis and management of NMIBC
patients in the EAU guidelines, NICE guidelines as well as a number of
country specific guidelines across Europe. The EAU guidelines for the
management of non-muscle invasive bladder cancer (NMIBC) have been developed
after thorough assessment of all clinical, safety and outcomes evidence to
provide recommendations on the best practice for managing these patients,
from diagnosis through treatment.

However, there is currently considerable variability across Europe with
adherence to EAU guidelines, as reported in a poster presentation by Dr. E.
N. Xylinas, Cochin Hospital, Paris Descartes University. "Improved adherence
to the EAU guidelines on the management of patients with NMIBC would ensure
all patients across Europe have access and may benefit from the optimal
methods for detecting and managing the disease like Hexvix Blue-Light
cystoscopy" concludes Dr. Xylinas.

For further information, please contact:

Kjetil Hestdal
President and CEO
Photocure ASA
Tel. +47 913 19 535
KH@photocure.com

About Photocure ASA

Photocure ASA, headquartered in Oslo, Norway, is a specialty pharmaceutical
company and world leader in photodynamic technology. Based on our unique
propriety Photocure Technology® platform, Photocure develops and
commercializes highly selective and effective solutions in disease areas with
high unmet medical needs such as bladder cancer, HPV and precancerous
cervical lesions, colorectal cancer and skin conditions. Our aim is to
provide solutions that can improve health outcomes for patients worldwide.
Photocure is listed on the stock exchange (OSE: PHO). Information about
Photocure is available at www.photocure.com

About Hexvix®/Cysview®(USA name)

Hexvix®/Cysview® (hexaminolevulinate hydro-chloride) is an innovative
breakthrough technology in the diagnosis and management of
non-muscle-invasive bladder cancer. It is designed to selectively target
malignant cells in the bladder and induce fluorescence during a cystoscopic
procedure using a blue light enabled cystoscope. Using Hexvix®/Cysview® as an
adjunct to standard white light cystoscopy enables the urologist to better
detect and remove lesions, leading to a reduced risk of recurrence.
Hexvix®/Cysview® is approved in Europe, USA and Canada.

About bladder cancer

Bladder cancer is the fifth most common cancer in men with more than 330 000
new cases annually and more than 130 000 die of the disease. It has a high
recurrence rate with an average of 61% in one year and 78% over five years,
making the lifetime costs of managing bladder cancer one of the highest
amongst all cancers. It is a costly, potentially progressive disease for
which patients have to undergo multiple surveillance cystoscopies because of
the high risk of recurrence. A recent paper on the economic burden of bladder
cancer across the European Union estimates that bladder cancer cost the EU
4,9 billion Euro in 2012.There is an urgent need to improve both the
diagnosis and the management of bladder cancer for the benefit of patients
and healthcare systems alike.

This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Photocure ASA via Globenewswire

HUG#1993923

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.